MedPath

Halaven

HALAVEN (eribulin mesylate) injection 0.5 mg/mL

Approved
Approval ID

8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 22, 2023

Manufacturers
FDA

BSP Pharmaceuticals SpA

DUNS: 857007830

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

eribulin mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code43624-002
Application NumberNDA201532
Product Classification
M
Marketing Category
C73594
G
Generic Name
eribulin mesylate
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 22, 2023
FDA Product Classification

INGREDIENTS (3)

ERIBULIN MESYLATEActive
Quantity: 0.5 mg in 1 mL
Code: AV9U0660CW
Classification: ACTIB
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Halaven - FDA Drug Approval Details